Evaluating UK national guidance for screening of children for tuberculosis. A prospective multicenter study by Kampmann, Beate et al.
 
 
 
 
 
Kampmann, B. et al. (2018) Evaluating UK national guidance for screening 
of children for TB: a prospective multi-centre study.American Journal of 
Respiratory and Critical Care Medicine, 
197(8), (doi:10.1164/rccm.201707-1487OC) (PMID:29190430) 
 
This is the author’s final accepted version. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 
http://eprints.gla.ac.uk/152953/    
                    
 
 
 
 
 
 
Deposited on: 04 December 2018 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk  
 
  
Evaluating UK national guidance for screening of children for TB: a 
prospective multi-centre study 
 
Authors  
Beate Kampmann1,13, James A Seddon1, James Paton2, Zohreh Nademi3 ,4, Denis 
Keane1, Bhanu Williams5, Amanda Williams5, Sue Liebeschutz6, Anna Riddell7, 
Jolanta Bernatoniene8, Sanjay Patel9, Nuria Martinez10, Paddy McMaster11, 
Robindra Basu-Roy1, Steven B Welch12 
 
Corresponding author 
Professor Beate Kampmann 
Centre of International Child Health 
Department of Paediatrics 
Imperial College London 
Norfolk Place 
London W2 1PG 
b.kampmann@imperial.ac.uk 
Phone: +44 20 7594 2758 
Fax: +44 20 7594 3894 
 
 
Affiliations 
1Centre of International Child Health, Department of Academic Paediatrics, 
Imperial College London, Norfolk Place, London W2 1PG, UK 
2School of Medicine, College of Medical, Veterinary, and Life Sciences, University 
of Glasgow, Govan Road, Glasgow G51 4TF, UK 
3Department of Paediatrics, Great North Children Hospital, Newcastle upon Tyne, 
Tyne and Wear NE1 4LP, UK 
4Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, Tyne 
and Wear NE1 7RU, UK 
5Department of Paediatrics, London North West Healthcare NHS Trust, 
Northwick Park Hospital, Watford Road, Harrow, Middlesex HA1 3UJ, UK 
Page 1 of 28  AJRCCM Articles in Press. Published on 30-November-2017 as 10.1164/rccm.201707-1487OC 
 Copyright © 2017 by the American Thoracic Society 
  2
6Department of Paediatrics, Newham University Hospital, Barts Health NHS 
Trust, Glen Road, Plaistow, London E13 8SL, UK 
7The Children's Hospital at the Royal London Hospital, Barts Health NHS Trust, 
Whitechapel Road, Whitechapel, London E1 1BB, UK 
8Department of Paediatric Infectious Diseases, Bristol Royal Hospital for 
Children, Paul O'Gorman Building, Upper Maudlin St, Bristol BS2 8BJ, UK 
9Department of Paediatric Infectious Diseases and Immunology, Southampton 
Children's Hospital, 119 Tremona Road, Southampton SO16 6HU, UK 
10Department of Paediatric Infectious Diseases, Evelina Children’s Hospital, 
Westminster Bridge Road, London SE1 7EH, UK 
11Department of Paediatric Infectious Diseases, North Manchester General 
Hospital, Delaunays Road, Crumpsall, Manchester M8 5RB, UK 
12Birmingham Chest Clinic, Heart of England NHS Foundation Trust, Bordesley 
Green East, Birmingham, West Midlands B9 5SS, UK 
13Vaccines & Immunity Theme, Medical Research Council (MRC) Unit The 
Gambia, Atlantic Boulevard, Gambia 
 
Authorship Contributions 
BK devised the original idea for the study and obtained its funding. All authors 
were involved in the development of the study protocol, enrolment of patients 
and data collection.  BK led the data analysis and interpretation of the findings 
with input from all authors. BK, JAS, SW and JP drafted the first version of the 
article; all authors contributed to critical review and amendments and approved 
the final version. BK is the guarantor. 
 
Funding 
This work was funded by a NIHR Senior Research Fellowship to BK (NIHR/SRF-
2009-02-07). JAS was supported by an NIHR Academic Clinical Lectureship and 
also through grants from the Academy of Medical Sciences and the BRC. The 
research and DK were supported by the National Institute for Health Research 
(NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS 
Trust and Imperial College London. The funders had no role in study design; in 
Page 2 of 28 AJRCCM Articles in Press. Published on 30-November-2017 as 10.1164/rccm.201707-1487OC 
 Copyright © 2017 by the American Thoracic Society 
  3
the collection, analysis, and interpretation of data; in the writing of the report; 
and in the decision to submit the article for publication. 
 
Running Head: 
Evaluating UK national guidance for childhood TB infection 
 
 
Descriptor 
11.1 Diagnosis of Tuberculosis or Latent Infection in children 
  
Word count 
Main Text:  3706 
 
This article has an online data supplement, which is accessible from this issue's 
table of content online at www.atsjournals.org 
 
At a Glance Commentary 
What is the current scientific knowledge on this subject?  
The safest and most effective strategies for recognition and treatment of TB 
infection in children remain to be defined, and national recommendations vary 
between countries. 
 
What does this study add to the field?  
In the low prevalence setting of the UK and over a follow up period of 2 years, we 
saw no incident cases of TB disease in children over the age of two years who had 
a positive tuberculin skin test (TST) but remained interferon-gamma release 
assay (IGRA) negative and did not receive treatment for TB infection. 
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ABSTRACT 
Rationale and Objective 
In order to identify infected contacts of tuberculosis (TB) cases, the UK National 
Institute for Health and Care Excellence (NICE) recommended the addition of 
interferon-gamma release assays (IGRA) to the tuberculin skin test (TST) in its 
2006 TB guidelines. Treatment for TB infection was no longer recommended for 
children screened TST-positive but IGRA-negative. We carried out a cohort study 
to evaluate the risk of TB disease in this group.  
Methods 
Children exposed to an infectious case of TB in their household were recruited 
from 11 paediatric TB clinics. TST and IGRA were carried out at baseline, IGRA 
repeated at 8 weeks and TST repeated if initially negative. Children were treated 
according to 2006 NICE guidelines and followed for 24 months.  
Measurements and Main Results 
Of 431 recruited children 392 completed the study. We diagnosed 48 (12.2%) 
cases of prevalent TB disease, 105 (26.8%) with TB infection and 239 (60.9%) 
without TB infection or disease. 18 children aged two years and above had a 
positive TST but persistently negative IGRA. None received TB infection 
treatment and none developed TB disease. 90 (26.1%) children qualified for TB 
infection treatment according to 2006 NICE guidelines. In contrast, 147 (42.7%) 
children would have qualified under revised NICE guidance, issued in 2016.  
Conclusions 
In this low prevalence setting we saw no incident cases of TB disease in children 
who were TST-positive but IGRA-negative and did not receive treatment for TB 
infection. Following the latest NICE guidance, significantly more children will 
require medication. 
 
Word Count Abstract: 250 
 
Key words:  Childhood tuberculosis, Diagnosis of TB infection, Interferon-
gamma release assays  
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INTRODUCTION 
 
Latest estimates by the World Health Organization (WHO) suggest that around 
one million children globally develop tuberculosis (TB) disease every year, and 
210,000 die of this potentially preventable and treatable infectious disease.1 For 
most children, exposure to TB occurs through an adult in their household. 
Following exposure about half of household contacts become infected2 and once 
infected, the risk of disease progression is highest in the first 12 months.3 The 
risk is heavily influenced by the age of the child at the time of infection: the 
youngest children are at the highest risk.4 For these reasons, the WHO 
recommends that treatment of TB infection (also known as preventive therapy, 
isoniazid preventive therapy or latent tuberculosis treatment) be provided to all 
children under the age of five years who have recently been exposed to an adult 
with infectious TB in their household.5,6 The post-2015 WHO End TB Strategy 
provides a target to reduce, by 2035, the global TB incidence by 90% compared 
to current levels.7 Modelling studies suggest that reductions of this magnitude 
will not be possible unless cases of TB infection are treated in addition to TB 
disease.8,9 
 
In the UK, the public health services (Public Health England, PHE) and the 
National Health Service (NHS) function in an integrated fashion: all cases of 
potentially infectious TB disease are notified to PHE and screened by clinical TB 
nursing teams, who identify household and other close contacts within NHS 
facilities. In England, 5,758 cases of tuberculosis were reported in 2015.10 
National policy, for many years, has been that household members of these cases, 
together with other close contacts, should be screened to identify any additional 
cases of TB disease, as well as any individuals with TB infection who might 
benefit from TB infection treatment. However, there has been much debate on 
which screening tools to use, especially for children.11-13 In 2006, the National 
Institute for Health and Care Excellence (NICE) in the United Kingdom (UK) 
issued guidelines for the screening of those exposed to TB, which, for the first 
time, introduced interferon-gamma release assays (IGRA), a then novel blood-
based assay, into the screening algorithm.14 Up until that point testing for 
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evidence of sensitisation to M. tuberculosis had been via the tuberculin skin test 
(TST). Unlike the TST, IGRAs are designed to distinguish between a “false-
positive” TST, due to sensitisation by non-pathogenic mycobacteria including due 
to previous BCG vaccine, and “true” infection with M. tuberculosis by using 
antigens encoded by genes located within the region of difference 1 segment of 
the M. tuberculosis genome in the test,15,16 leading to somewhat greater 
specificity.17 In the 2006 NICE algorithm, IGRA tests were recommended in TST-
positive individuals and only those found to be both TST- and IGRA-positive were 
to receive treatment for TB infection. BCG vaccination history was used to decide 
on the size of the TST induration that was required to classify the test as positive, 
therefore directly influencing which children would progress to IGRA testing. 
This algorithm was applied to all individuals older than 2 years of age, and, as a 
consequence, children who were found to be TST-positive but IGRA-negative no 
longer qualified for TB infection treatment. Given the lack of data on the 
performance of IGRAs in children, paediatricians conducting TB contact 
investigations in the UK were concerned as to whether this new policy was safe.18 
 
In response to these concerns, we set up a multi-centre, multi-site study within 
the National Health Service (NHS), the NIHR-funded IGRA Kids Study (NIKS).19 
Our primary objective was to measure incident TB disease in TST-positive but 
IGRA-negative children over a 2-year follow up period. Our secondary objectives 
were to ascertain the percentage of children who were TST-negative but IGRA-
positive at baseline and who would have been missed by the 2006 NICE 
screening algorithm, and to determine the proportion of children who converted 
their TST and/or IGRA from negative to positive between baseline and follow-up 
at 8 weeks in order to assess the added value of repeat screening.  After NIKS 
completed recruitment but prior to data analysis, the NICE guidance was 
updated.20 The 2016 version now recommends treating all children for TB 
infection if they have a TST result ≥5mm, independent of IGRA results and BCG 
vaccination history. Given the availability of our substantive dataset, we 
therefore also evaluated the implications of these latest recommendations for 
clinical practice. 
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 METHODS 
 
Study Setting 
Between 1st Jan 2011 and 31st Dec 2014, children were recruited from five 
paediatric TB clinics in London, together with paediatric TB clinics in 
Southampton, Bristol, Birmingham, Manchester, Glasgow and Newcastle. An 
identical protocol was used at all sites and children were followed for 24 months. 
The study was funded by the NIHR and Comprehensive Local Research Network 
(CLRN) support was provided at the different study sites. 
 
Study procedures  
Ethical Approval: The study was approved by the UK National Research Ethics 
Service (REC: 11/11/11). Parents of all children included in the study provided 
written informed consent, with additional assent in older children.  
Recruitment: In line with national guidelines, all  contacts are screened by history 
for potential TB symptoms or underlying susceptibility to TB, and are then 
invited for TST and/or IGRA screening. Detailed procedures of recruitment to the 
NIKS study have previously been described.19 In brief, parents/guardians of 
children attending for contact screening were approached for entry into the NIKS 
study and referred to participating clinics where children were evaluated by the 
study paediatricians. Evaluations included history, examination, TST and IGRA 
tests, chest radiography, microbiology and HIV testing where appropriate. The 
decision to provide treatment for TB infection to contacts with evidence of TB 
infection was based on the 2006 NICE guidelines for children above the age of 2 
years. As we aimed to evaluate the utility of TST and IGRA testing in child 
contacts, children with a prior history of a positive test of TB infection were not 
included. BCG vaccination status: If a BCG scar was present, children were 
classified as BCG-vaccinated. If no scar was seen, but there was clear 
documentation in paper or electronic records, or if the parents gave a clear 
history of vaccination, the child was classified as BCG-vaccinated. Otherwise the 
child was classified as BCG-unvaccinated. Evidence of TB infection: Both TST and 
IGRA were carried out simultaneously at the first screening visit. TST was placed 
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by experienced members of the TB nursing teams, by injecting two tuberculin 
units (purified protein derivative RT23, Statens Serum Institute) intradermally 
with results read within 48-72 hours. IGRA tests (either QuantiFERON-TB Gold 
In-Tube [Quiagen] or T-SPOT.TB [Oxford Immunotec Ltd] were carried out in 
clinical laboratories of the respective NHS Trusts, following routine practice in 
the Healthcare Trust and the relevant manufacturers’ instructions for processing. 
IGRA testing was repeated in all children after 8 weeks, as was TST if initially 
negative. IGRA results were interpreted as positive, negative or indeterminate in 
line with the standard clinical laboratory reporting practice. A child was 
classified as IGRA-positive (classified as TB infected) if either the baseline or the 
8-week IGRA were positive and there was no evidence of TB disease. All children 
with a negative IGRA at both timepoints were classified as TB exposed but 
uninfected. An IGRA which was indeterminate twice would also be assigned as 
negative, and the child classified as TB exposed but uninfected. TST was defined 
as positive if the transverse diameter of the induration was ≥6 mm in BCG-
unvaccinated children and ≥15mm in previously vaccinated children, as per 2006 
NICE guidance. TST conversion was defined, in BCG-vaccinated children, as a TST 
induration at 6-8 weeks of  ≥15mm with an increase from baseline of >5mm; in 
BCG-unvaccinated children it was defined as a TST induration at 6-8 weeks of 
≥6mm with an increase from baseline of >5mm. The differences between the 
2006 NICE guidance, the NIKS protocol and the 2016 NICE guidance are 
summarised in the supplementary table 1.   
 
Statistical analysis:  
Data were entered into a secure online database in real-time and later checked 
centrally for entry errors. Data were analysed using STATA software (version 11; 
Stata Corp, College Station, TX). Missing data were excluded from analysis. 
 
Clinical Management 
Children with confirmed or clinically-diagnosed TB disease were managed 
according to standard treatment protocols.21 All children younger than 1 year of 
age at the time of enrolment, found to not have TB disease, were offered three 
months of isoniazid and rifampicin, independent of BCG vaccination status or 
Page 8 of 28 AJRCCM Articles in Press. Published on 30-November-2017 as 10.1164/rccm.201707-1487OC 
 Copyright © 2017 by the American Thoracic Society 
  9
TST/IGRA results. All children aged between one and two years, were 
commenced, once TB disease had been excluded, on isoniazid and rifampicin, 
with medication stopped if they remained negative on repeat testing of both TST 
and IGRA after 6-8 weeks. If either of these tests became positive, they were re-
evaluated clinically to exclude TB diseases, and completed three months of TB 
infection treatment. Children older than 2 years with evidence of TB infection as 
determined by a positive IGRA test were given treatment for TB infection with 
three months of isoniazid and rifampicin. Following the completion of baseline 
and 8 week screenings, all children identified as TB exposed but with persistently 
negative TST and IGRA were offered BCG vaccination, if not previously 
immunised. All children were observed for 24 months with 3-monthly 
appointments in year 1 and 6 monthly in year two. 
 
Outcome Definitions 
In the study protocol, prevalent TB was defined as TB disease diagnosed at the 
time of screening or within the subsequent 8 weeks. Incident TB was defined as 
TB disease diagnosed, in a child TB disease-free at baseline, at any time after the 
8 week during the 2-year follow up. TB infection was defined by IGRA positivity 
in the absence of TB disease. Children without evidence of TB infection or disease 
were classified as TB exposed but uninfected.  
 
 
RESULTS 
 
In total, we enrolled 431 children; 357 (83%) were >2 years. Cohort details are 
summarised in Table 1. Data from 39 children were subsequently excluded as 32 
withdrew after their first visit, 4 had a change of diagnosis and 3 were treated 
with isoniazid and rifampicin outside of the agreed protocol. All outcome 
measures reported subsequently therefore relate to the 392 children who 
completed the study. Demographic details of the children who withdrew were 
not significantly different from those who completed the study, and there were 
no significant differences in the clinic populations in potentially confounding 
parameters such as age and sex. We diagnosed 48 cases of prevalent TB disease 
(12.2%), 105 children with evidence of TB infection (26.7%) and 239 children 
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(60.9%) without any evidence of TB infection or disease. There were no cases of 
incident TB during the follow-up period. Of the 48 children with prevalent TB 
disease, all were diagnosed with pulmonary TB within the first 8 weeks of 
assessment; 33 (68.7%) had samples sent for microbiological testing with 
confirmation of M. tuberculosis in 13/33 (39.4%). The remaining 35 (72.9%) 
were diagnosed with TB disease on clinical criteria alone. Table 2 summarises 
the baseline characteristics of the study participants, categorised according to 
final outcome. The management of the 239 children classified as TB exposed but 
not infected is indicated in Table 3.  
 
Of 344 children without prevalent TB, 251 (72.9%) were IGRA-negative at 
baseline, 80 IGRA-positive (23.2%) and 13 (3.8%) had indeterminate results 
(Figure 1). In comparison, 249 were TST-negative (72.3%) and 95 were TST-
positive (27.6%). Overall, IGRA and TST results were concordant in 287 of 344 
children (83.4%). At baseline, 28 (29.5%) children were TST-positive and IGRA-
negative, and 16 (6.4%) children were IGRA-positive and TST-negative (Table 
4). Follow-up was undertaken at 8 weeks, and 311 of the 344 (90.4%) children 
had a repeat IGRA. The missing IGRA tests were primarily in the group of 
children already found to be IGRA positive at baseline. Of these 311 children, 273 
(87.7%) did not show any differences in IGRA status between baseline and 8 
weeks. A change from negative to positive was found in 18 (5.7%) children re-
tested and from indeterminate to positive in 7 (2.2%). A change from positive to 
negative was noted in 8 (2.5%), and from indeterminate to negative in a further 6 
(1.9%). The rate of indeterminate IGRA results was 3.8% (13/344) at baseline 
and 2.9% (9/311) at 8 weeks. Only one child had an indeterminate IGRA twice.  
 
In line with the study protocol, TST was only repeated in children with a negative 
baseline TST; of 249 eligible children, 239 (96.0%) underwent the repeat 
procedure, with 25 (10.4%) found to have converted their TST to positive 8 
weeks later. Ten (40%) of this group of children also converted their IGRA result 
from negative to positive. 28 children were TST-positive but IGRA-negative at 
baseline and 18 remained IGRA-negative on repeat screening; the remainder 
becoming IGRA-positive. Of these 18, three fell into the under-2 years of age 
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category and were given isoniazid and rifampicin (either for the full 3 months, if 
under 1 year, or until re-testing, if between 1 and 2 years), hence their outcome 
data could not be included in the primary analysis. The other 15 did not receive 
any treatment and none developed TB disease during the 2 years of follow-up. In 
16 of 249 children (6.4%), the baseline IGRA was positive while the TST was 
negative. 10 of these children received a second TST, of whom 5 had converted 
from negative to positive on repeat screening 8 weeks later.  
 
Applying the 2006 NICE guidance algorithm, 90 (26.1%) children qualified for 
treatment of TB infection on the basis of their TST and subsequent IGRA results. 
Using the 2016 NICE guidance, 147 (42.7%) children would have been prescribed 
treatment for TB infection, based on their TST result. This represents a 63% 
increase. 52 (35.3%) of the 147 children in this group would have tested IGRA-
negative. In the group with positive IGRA but a TST defined as negative, 12 out of 
16 (75%) would have qualified for treatment of TB infection according to 2016 
NICE guidance. However, 4/16 (25%) would still have remained undetected, as 
they were IGRA-positive with a TST below 5mm. 
 
 
DISCUSSION 
 
Our study set out to measure incident TB disease in TST-positive but IGRA-
negative children who had documented exposure to a household contact with 
infectious TB, in order to estimate the negative predictive value of IGRA for the 
development of TB, following the 2006 NICE guidance. We also examine 
concordance between TST and IGRA in the low prevalence setting of the UK.  
We enrolled the largest, prospectively recruited cohort of TB-exposed children in 
the UK to date. In comparison to other studies of IGRA testing in young children, 
we encountered a low rate of indeterminate results.13,22 In this low prevalence 
setting, and over 24 months of follow up, we saw no incident cases of TB disease 
in 18 children older than two years who were TST-positive but remained IGRA 
negative and did not receive treatment. A large proportion of exposed children 
remained uninfected in our study, with only a small percentage of children being 
Page 11 of 28  AJRCCM Articles in Press. Published on 30-November-2017 as 10.1164/rccm.201707-1487OC 
 Copyright © 2017 by the American Thoracic Society 
  12
TST positive but IGRA negative. This is in contrast to other studies reported in 
the literature, where the proportion of children found to have TB infection 
following household exposure has been described as anywhere between 16 and 
76 percent, depending on criteria and TST cut-off used.2 We believe that despite 
the size of the cohort, we ultimately had insufficient power to definitively answer 
the primary study question, given that we had a much smaller than anticipated 
cohort of children with a positive TST but negative IGRA, which was further 
reduced by employing a second IGRA screening assay. 
 
Our results do not fully reflect the reality of screening procedures within national 
TB guidelines, where TST and IGRA are not usually used simultaneously. We 
deliberately chose this study design in order to assess the level of concordance 
between the two screening tests and to measure any potential “missed 
opportunities” where a step-wise approach of TST first, followed by IGRA (if TST-
positive) was employed. Conducting IGRA and TST at the same time therefore 
enabled us to assess how many IGRA-positive children would have been missed if 
only those with a positive TST received a subsequent IGRA. At baseline screening, 
this result was 6.4 %, but with repeat screening, half of this group had converted 
their IGRA and therefore would have qualified for treatment of TB infection 
ultimately. Our data show high concordance between TST and IGRA and, 
importantly, that on repeat testing the majority of children who converted their 
TST also converted their IGRA. The value of contact tracing in TB-exposed 
children was confirmed by the high yield of prevalent TB disease at the time of 
contact investigations: 12.2% of child contacts were diagnosed with TB disease. 
This is also in the context of a very strict definition of prevalent TB. Other studies 
have used a longer time interval to define prevalent TB disease. The study by 
Anger and colleagues, similarly demonstrated the importance of contact 
investigation as an active case finding activity, though they used a longer time 
interval with to define prevalent cases with contacts diagnosed with TB disease 
as late as 9 months after the index case. 23  
 
Our study has some limitations. Since TB infection treatment is nationally 
recommended for children under the age of two years exposed to an infectious 
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case of TB, it would not have been appropriate to withhold such an intervention. 
The positive predictive value of IGRA for progression to TB disease cannot be 
established in our cohort, given its size, nor has it been conclusively 
demonstrated for children, who have generally been excluded from studies 
evaluating IGRA to predict disease progression or represented only a very small 
proportion of participant.24,25 Given our protocol, we identified a higher 
proportion of children who qualified for TB infection treatment than the 2006 
NICE algorithm would have determined. We therefore may have prevented some 
of the incident cases than might have occurred otherwise. Additionally, we 
cannot comment on the negative predictive value of IGRA in children under the 
age of two years, as we uniformly gave TB infection treatment to this group, given 
their acknowledged vulnerability. However, these children only represented 10% 
of the cohort. 
 
In January 2016, the NICE guidance for TB screening was revised and it was 
recommended that a history of BCG vaccination should no longer be taken into 
account in the interpretation of the TST result.20 Despite certain operational 
advantages for the use of IGRA, such as no need for return to the clinic if the 
result is negative, the cost effectiveness evaluation in the UK now favours the use 
of TST in its last version of the national guidance.  A lower universal cut-off of 
5mm was introduced to define TST-positivity; any child with a TST equal to or 
greater than 5mm should now receive treatment for TB infection. IGRA testing 
was left to the discretion of the treating health care professionals. Applying this 
new guidance to the data from our cohort, 63% more children would have 
qualified for treatment, a significant increase in the need for medication and use 
of NHS resources, including TB nurse time. All of these additional children would 
have been IGRA-negative. Only four children in our cohort were IGRA-positive 
with a TST result below 5 mm and these would not have been picked up by the 
2016 screening algorithm. Of 344 children in a low prevalence setting, this 
represents a relatively small at-risk group.  
 
The WHO End TB Strategy aims for effective TB elimination and places a 
significant emphasis on the treatment of TB infection in addition to TB disease.7 
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Children, following household exposure, are at very high risk for TB infection and 
subsequent disease progression. They have been identified as a group that should 
be at high priority for evaluation and TB infection treatment 5 and the latest Stop 
TB plan for elimination of tuberculosis places particular emphasis on treatment 
of latent infection in children. The WHO currently recommends that following 
exposure to an infectious TB case all children under five years should be offered 
treatment for TB infection without any immune-based screening tests.26 If TST is 
to be used, WHO advises a 10mm cut-off. In the UK, TB infection treatment is now 
offered to all individuals with evidence of TB infection up to the age of 65 years. 
The current NICE guideline does not distinguish between the management of 
adults and children, with the same protocol used for both groups. This is 
probably with the aim of facilitating the programmatic delivery of TB care. Whilst 
the previous NICE guidance was deemed over-complicated with its use of 
different TST cut-offs in BCG-vaccinated and -unvaccinated individuals, the 
revised version simplifies the approach significantly. Previously published data 
from the NIKS cohort showed the age-related impact of BCG vaccination on TST 
interpretation, with a cut off of 10 mm increasing specificity after the age of two 
years.19 It could be argued that by introducing a 5mm TST cut-off, the use of IGRA 
testing is now obsolete. We might therefore have come full circle after years of 
discussing the merits of a more specific test for TB infection. However, an 
additional and ongoing challenge has arisen due to the limited availability of 
tuberculin internationally, and as a consequence many hospital trusts are 
currently using IGRA, despite NICE guidance.27  
The current UK screening practice in otherwise well children with household 
exposure relies exclusively on TST, with a smaller cut-off than advised by other 
international guidance. This has the advantage of being a sensitive 
and   straightforward approach from a screening program perspective, but 
it leads to increased numbers of children being treated, likely 
some unnecessarily. Recent guidance from the United States has moved towards 
an approach based almost entirely on the use of IGRA rather than TST.27 Despite 
the somewhat limited study size, our data suggest a high reliability of IGRA 
testing in children above the age of two years. No screening test perfectly 
predicts risk of progression to disease, and it is important to invest effort in 
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retention in screening and treatment programs as well as optimising the 
screening test.  A pragmatic recommendation, supported by our data, would be 
simply to treat all children under the age of 2 for TB infection, following 
household exposure, once TB disease has been excluded.  In children older than 2 
who are otherwise healthy, our data support using IGRA without TST for 
screening, with treatment for TB infection restricted to those who have tested 
positive on IGRA alone.  
In conclusion, in this low prevalence setting we saw no incident cases of TB 
disease in children above the age of two years who were TST-positive but IGRA-
negative and did not receive treatment for TB infection. Following the latest NICE 
guidance, significantly more children will require medication.  
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TABLES 
Table 1:  Demographic details and recruitment sites for children in contact 
with an infectious case of tuberculosis 
 
Characteristic n  (%) 
Total 431 100 
Age (median, IQR)  6 (2.5-11)  
Age (years) <1 42 9.7 
 1-2 32 7.4 
 above 2 357 82.8 
Gender Male 224 51.9 
 Female 207 48.1 
   
Ethnicity White 105 24.3 
 Indian 59 13.7 
 Pakistani 84 19.5 
 Bangladeshi 40 9.3 
 
Black-
Caribbean 
3 
0.7 
 Black-African 91 21.1 
 Black-Other 10 2.3 
 Chinese 1 0.2 
 
Mixed / 
Other 
38 
8.8 
Place of birth UK 353 81.9 
 Born abroad 78 18.1 
Recruitment Site 
Barts, 
London 
39 
9.0 
 Birmingham 77 17.9 
 Bristol 30 7.0 
 Evelina, 
London 
16 3.7 
 Newcastle 74 17.2 
 Newham 61 14.1 
 Northwick 
Park, London 
53 12.3 
 Southampton 16 3.7 
 St. Mary’s, 
London 
20 4.6 
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 Manchester/ 
Royal 
Oldham 
6 1.4 
 Yorkhill, 
Glasgow 
39 9.0 
 
IQR=interquartile range 
 
 
Table 2: Demographic data, TST and IGRA results of the study participants 
at baseline screening. Participants are classified according to final outcome 
category. 
 
 
 
All included 
contacts  
(N=, %) 
prevalent 
TB 
disease 
(N=, %) 
TB 
Infection 
(N=, %) 
TB-exposed 
and 
uninfected 
(N=, %) 
Total according to final outcome 392 (100) 48 (12.2) 105 (26.8) 239(60.9) 
Age in years (median, IQR) 
 
6 (2.5-11) 
 
4.5 (2-12) 
 
8 (5-11) 5 (2-10) 
 
<1 39 (9.9) 3 (6.2) 4 (3.8) 32 (13.4) 
1-2 31(7.9) 5 (10.4) 2 (1.9) 24 (10.0) 
 >2 322 (82.1) 40 (83.3) 99 (94.2) 183 (76.6) 
Gender Male 200 (51.0) 25 (52.0) 51 (48.6) 124 (51.9) 
 Female 192 (49.0) 23 (48.0) 54 (51.4) 115 (48.1) 
Born in the UK 
 
320 (81.7) 
 
36 (75.0) 
 
82 (78.0) 
 
202 (84.5) 
Born abroad 
 
72 (18.3) 
12 (25.0) 23 (21.9) 37 (15.5) 
Previously BCG vaccinated 
 
281 (71.6) 
 
29 (60.4) 
 
69 (65.7) 183 (75.7) 
TST  
 
positive 131 (33.4) 36 (75.0) 74 (70.4) 21(8.8) 
negative 261 (66.6) 12 (25.0) 31 (29.5) 218 (91.2) 
IGRA 
 
Positive 120 (30.6) 40 (83.3) 80 (76.1) 0 (0) 
Negative 258 (65.8) 7 (14.6) 21 (20.0) 230 (96.2) 
Indeterminate 14 (3.6) 1 (2.1) 4 (3.9) 9 (3.8) 
 
TB: tuberculosis; IGRA: interferon-gamma release assay; TST: tuberculin skin 
test; IQR: interquartile range  
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Table 3: Clinical management of uninfected children that were exposed to TB 
 
Management  Number (%) 
Total number of TB exposed, uninfected 239 (100) 
Preventive Therapy, no BCG given 47  (19.7) 
Preventive Therapy, BCG given 15    (6.3) 
No preventive therapy required, BCG given 20    (8.4) 
No preventive therapy required, no BCG given 157 (65.6) 
 
BCG: Bacillus Calmette–Guérin 
 
 
 
 
 
 
Table 4: Concordance of TST and IGRA results in children evaluated as 
household contacts at baseline screening (cases of prevalent TB excluded) 
 
 
 IGRA positive 
(n=80) 
IGRA negative 
(n=251) 
IGRA 
indeterminate 
(n=13) 
TST positive 
(n=95) 
 
64 (67.4) 28 (29.5) 3 (3.1) 
TST negative 
(n=249) 
 
16 (6.4%) 223 (89.5) 10 (4.01) 
 
TST: tuberculin skin test; IGRA: interferon-gamma release assay 
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Figure 1: Study design flow diagram 
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(n=64)
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TST	negative
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IGRA	remained	
negative	on	repeat	
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Figure 1
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SUPPLEMENTARY MATERIAL 
 
Supplementary Table E1: Comparison of Nice guidelines 2006, 2016 and the NIKS study 
protocol overall (a) and by age-specific criteria (b), (c), (d) 
 
 
 
E1a  
Age-
specific 
range 
Protocol 
component 
NICE 2006 NIKS Study 
Protocol 
NICE 2016 
All 
children 
except 
where 
specified.  
Thresholds 
for TST 
If BCG vaccinated, positive TST if ≥15mm 
If BCG unvaccinated, positive TST if ≥6mm 
Positive TST if 
≥5mm, 
independent of 
BCG status 
Index case 
definition 
Smear positive pulmonary TB for 
contacts who are under 2 years of 
age. 
 
Active TB for paediatric contacts over 
2 years of age. 
 
Smear- and/or 
culture-positive 
pulmonary TB 
contact in either 
the same 
household or 
within other 
members of the 
family in direct 
social contact 
Smear-positive 
pulmonary or 
laryngeal TB 
who have not 
had at 
least 2 weeks of 
anti-TB 
treatment 
 
If <2 years and 
index case 
smear negative 
refer to 
specialist. 
Clinical 
evaluation 
At any point if symptomatic, TST positive, or IGRA positive, assess for active 
TB prior to decision to treat for latent TB infection 
Regimen if 
treating for 
latent TB 
infection 
6/12 INH or 3/12 INH/RIF 3/12 INH/RIF 3/12 INH/RIF 
(with pyridoxine) 
or 6/12 INH 
(with pyridoxine) 
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E1b 
  
Age-
specific 
range 
Protocol 
component 
NICE 2006 NIKS Study 
Protocol 
NICE 2016 
1 
month 
to 12 
months 
Tests for 
latent TB 
infection 
If BCG 
vaccinated 
If not BCG 
vaccinated 
 
Baseline: TST 
& IGRA 
 
6-8 weeks: 
repeat TST 
and/or IGRA if 
initially negative 
(negative as 
defined per 
NICE 2006) 
 
 
 
Baseline TST 
 
If baseline TST 
is negative (<5 
mm), repeat TST 
at 6 weeks: 
 
if repeat TST is 
negative, 
consider IGRA. 
 
Baseline TST 
 
If baseline 
TST<15mm 
repeat after 6 
weeks. 
 
If at 6 weeks 
TST≥15mm and 
has increased 
from baseline 
induration by 
>5mm, do IGRA. 
 
Baseline TST 
 
If baseline 
TST<6mm repeat 
after 6 weeks. 
 
If at 6 weeks, 
TST≥6mm and 
has increased 
from baseline 
induration by 
>5mm, do IGRA. 
Management If BCG 
vaccinated 
If not BCG 
vaccinated 
 
All receive full 
treatment for 
latent TB 
infection. 
 
If 6-8 week 
TST-/IGRA-, 
BCG vaccinate 
(if no record) 
and discharge 
from follow-up 
after 
completion of 
treatment for 
latent TB 
infection. 
 
Initiate treatment 
for latent TB in 
all. 
 
If baseline & 6 
week TST and 
IGRA are 
negative, stop 
treatment for 
latent TB and 
give BCG 
vaccine if not 
given before. 
 
If baseline TST 
is positive 
complete 
treatment for 
latent TB. 
 
If baseline TST 
negative, but 
either 6 week 
TST or IGRA 
positive, 
complete 
treatment for 
latent TB. 
TST <15 mm at 
baseline and 6 
weeks, discharge 
(no medication) 
 
If IGRA indicated 
and negative, 
discharge at 6 
weeks. 
 
If IGRA indicated 
and positive, 
treat for latent TB 
infection 
 
 
 
If BCG 
unvaccinated, 
start INH 5mg/kg 
and do TST. 
If≥6mm, complete 
6/12 INH or 3/12 
INH/RIF. 
 
If TST<6mm, 
continue INH and 
repeat TST at 6 
weeks. If baseline 
and 6 week TST 
both negative, or 
6 week IGRA 
indicated and 
negative, stop 
INH at 6 weeks 
and BCG 
vaccinate. 
 
If IGRA indicated 
and positive, treat 
for latent TB 
infection 
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E1c  
Age-
specific 
range 
Protocol 
component 
NICE 2006 NIKS Study 
Protocol 
NICE 2016 
1-2 
years 
Tests for 
latent TB 
infection 
If BCG 
vaccinated 
If not BCG 
vaccinated 
 
Baseline: TST 
& IGRA 
 
6-8 weeks: 
repeat TST 
and/or IGRA if 
initially negative 
 
 
 
Baseline TST 
 
If baseline TST 
is negative, 
repeat TST at 6 
weeks: 
 
if repeat TST is 
negative, 
consider IGRA. 
 
Baseline TST 
 
If baseline 
TST<15mm 
repeat after 6 
weeks. 
 
If at 6 weeks 
TST≥15mm and 
has increased 
from baseline 
induration by 
>5mm, do IGRA. 
 
Baseline TST 
 
If baseline 
TST<6mm repeat 
after 6 weeks. 
 
If at 6 weeks, 
TST≥6mm and 
has increased 
from baseline 
induration by 
>5mm, do IGRA. 
Management If BCG 
vaccinated 
If not BCG 
vaccinated 
 
Initiate 
treatment for 
latent TB in all. 
 
If IGRA-/TST- 
or IGRA-/TST+ 
at 6-8 weeks, 
stop 
medication, 
BCG vaccinate 
(if no record). 
 
If IGRA+/TST+ 
or IGRA+/TST-, 
complete 3/12 
INH/RIF (no 
BCG vaccine). 
 
Initiate treatment 
for latent TB in 
all. 
 
If baseline & 6 
week TST and 
IGRA are 
negative, stop 
treatment for 
latent TB and 
give BCG 
vaccine if not 
given before. 
 
If baseline TST 
is positive 
complete 
treatment for 
latent TB. 
 
If baseline TST 
negative, but 
either 6 week 
TST or IGRA 
positive, 
complete 
treatment for 
latent TB. 
TST <15 mm at 
baseline and 6 
weeks, discharge 
(no medication) 
 
If IGRA indicated 
and negative, 
discharge at 6 
weeks. 
 
If IGRA indicated 
and positive, 
treat for latent TB 
infection 
 
 
 
If BCG 
unvaccinated, 
start INH 5mg/kg 
and do TST. 
If≥6mm, complete 
6/12 INH or 3/12 
INH/RIF. 
 
If TST<6mm, 
continue INH and 
repeat TST at 6 
weeks. If baseline 
and 6 week TST 
both negative, or 
6 week IGRA 
indicated and 
negative, stop 
INH at 6 weeks 
and BCG 
vaccinate. 
 
If IGRA indicated 
and positive, treat 
for latent TB 
infection 
Page 27 of 28  AJRCCM Articles in Press. Published on 30-November-2017 as 10.1164/rccm.201707-1487OC 
 Copyright © 2017 by the American Thoracic Society 
 4
 
E1d 
 
 
Age-
specific 
range 
Protocol 
component 
NICE 2006 NIKS Study 
Protocol 
NICE 
2016 
>2 
years 
Tests for 
latent TB 
infection 
If BCG 
vaccinated 
If not BCG vaccinated   
Baseline: 
TST & IGRA 
6-8 weeks: 
repeat TST 
and/or IGRA 
if initially 
negative 
 
 
 
Baseline 
TST 
 
If 
baseline 
TST 
negative 
(<5 mm), 
repeat 
TST and 
IGRA at 
6 weeks. 
 
Baseline 
TST 
If 
TST≥15mm 
then 
baseline 
IGRA. 
Baseline 
TST 
≥6mm  
Baseline TST<6mm 
 If contact 
smear 
positive 
If contact 
smear 
negative 
Perform 
baseline 
IGRA.  
 
 
Perform 
IGRA after 
6 weeks.  
No IGRA 
 Management If BCG 
vaccinated  
If not BCG vaccinated  
If 
IGRA+/TST+ 
or 
IGRA+/TST- 
at any point 
treat for 
latent 
infection. 
 
If IGRA-
/TST- BCG 
vaccinate (if 
no record) 
and 
discharge at 
6-8 weeks 
without 
medication. 
 
If IGRA-
/TST+ follow 
up as per 
study 
protocol and 
finally 
discharge 
without 
medication 
or BCG 
vaccination. 
 
If TST is 
positive 
(≥5mm), 
offer 
treatment 
for latent 
TB 
infection. 
 
If TST 
positive & 
IGRA 
positive, 
with CXR + 
clinical 
exam not 
suggestive 
of active TB, 
treat for TB 
infection. 
 
If initial TST 
negative, or 
TST positive 
but IGRA 
negative, 
inform and 
advise and 
discharge. 
 
If 
TST<15mm, 
discharge 
 
If IGRA 
negative, 
discharge.  
 
If IGRA 
positive, 
treat for 
TB 
infection. 
If IGRA 
negative, 
give BCG 
if not 
previously 
given and 
discharge. 
 
If IGRA 
positive, 
treat for 
TB 
infection. 
  
 
Give BCG 
if not 
previously 
given and 
discharge. 
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